It wasn’t until the final week in April that Celgene Corporation (NASDAQ: CELG) took the title of top deal maker for the month. The single acquisition on the books as of April 24 was its collaboration with MedImmune (NYSE: AZN) on its anti-PD-L1 inhibitor MEDI4736, with $450 million in cash upfront. On April 27, CELG announced it would pay another $110 million for Quantical Pharmaceuticals, followed two days later by two smaller licensing deals with Northern Biologics ($30 million) and Agios Pharmaceuticals (NASDAQ: AGIO) for $10 million. Then on April 30, it reported very rosy results for the first quarter, with total revenue up 20%, to $2.08 billion, and much, much more.